R Squared’s Abeona Therapeutics ABEO Stock Holding History

R Squared’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,160	Closed	-$23.2K	–	294
2024 Q4	$23.2K	Buy	+4,160	New	+$25.6K	0.02%	809

Other funds holding ABEO

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

R Squared's ABEO Position: Q1 2025 in Review

R Squared sold out of Abeona Therapeutics (ABEO) in Q1 2025, closing a stake of 4,160 shares — an estimated $23.2K sold.

R Squared first reported a position in ABEO in Q4 2024 and held it in 1 quarter. The position peaked at $23.2K in Q4 2024. 71 funds tracked by Wall St. Rank hold ABEO as of Q1 2025.

R Squared reported no remaining Abeona Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 4,160 Abeona Therapeutics shares in Q1 2025, an estimated $23.2K.
R Squared first reported a position in Abeona Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Abeona Therapeutics position peaked at $23.2K in Q4 2024.
71 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.